Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07468032

Dynamic Causal Modeling of Neuromodulation of Action Speed Via Targeted TMS-EEG

Stroke is a major cause of long-term disability, with cognitive and motor deficits-especially action slowing and executive dysfunction-being strong predictors of poor recovery outcomes. Recent advances in network neuroscience suggest that action speed is governed by interactions between specific prefrontal and premotor regions. However, the precise neural mechanisms underlying action slowing in stroke remain unclear, limiting the efficacy of current rehabilitation approaches. This study integrates high-density EEG, fNIRS and dynamic causal modeling (DCM), and rTMS to map and modulate the neural circuits involved in action speed. In the first phase, we will assess the role of seven key brain regions in action speed modulation by applying virtual lesions using single-pulse TMS in 60 healthy individuals. In the second phase, we will apply offline intermittent theta burst stimulation (iTBS) to the most relevant regions and evaluate its impact on action speed. Finally, in the clinical phase, we will administer individualized iTBS to 20 stroke patients to enhance action speed. Patients will be assessed at baseline, immediately post-treatment, and after one and three months to track improvements in action speed using DCM and behavioral tests. Changes in connectivity and action speed performance will be compared to healthy controls to refine treatment parameters. Secondary outcomes include executive function and daily life motor performance. Longitudinal follow-up will determine the persistence of improvements, informing future personalized rehabilitation strategies. By characterizing effective connectivity changes post-stroke, we aim to refine neuromodulation strategies and develop a personalized rTMS approach. Our hypothesis is that targeting specific regions identified through integration of EEG, fNIRS and DCM can enhance action speed, ultimately improving functional recovery. This personalized approach could lead to more effective rehabilitation protocols, tailored to individual brain damage patterns.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Amiens

Amiens, Picardie, 80000, France

Location status: Recruiting

Location contact

Ardalan Aarabi, Pr

SUB_INVESTIGATOR

Etienne Allart, Pr

PRINCIPAL_INVESTIGATOR

Hervé Devanne, Pr

SUB_INVESTIGATOR

Olivier Godefroy, MD-PhD

CONTACT

[email protected]

++33322668240

Pierre Morel, MD

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The control group consists of individuals who are :
  • neurologically healthy,
  • meaning they do not have any medical conditions that could interfere with cognitive performance or its measurement.
  • not have any contraindications for undergoing MRI scans or TMS, such as epilepsy, which could be triggered by magnetic stimulation.
  • The patient group will include :
  • individuals who have experienced a hemispheric stroke but with specific criteria ( stroke must not have affected key prefrontal regions that are targeted in the study, ensuring that the observed motor slowing is due to network dysfunction rather than direct structural damage to these regions)
  • be free of other cognitive impairments or medical conditions that could confound the study's results.

Exclusion criteria

  • participants with neurological,
  • psychiatric, or general conditions known to alter test performance or cognitive function, according to a previously validated method will be excluded.
  • any contraindication to MRI and TMS (e.g., epilepsy).
  • For stroke patients, the lesion delineated on MRI must spare the prefrontal target structures.

Treatment and study plan

Phase 1 functional MRI (fMRI)

Other

3D T1-weighted imaging (T1w) and (10 min) resting-state functional MRI (fMRI) will be acquired for each healthy subject to identify target regions for TMS interventions.

Phase 1 aims to assess the impact of temporary disruption (caused by virtual lesions (VL)) on action speed, measured by reaction time (RT) using a simple reaction time (SRT) task in healthy subjects

Phase 2 functional MRI (fMRI)

Other

Phase 2 will assess the effects of intermittent theta burst stimulation (iTBS) on improving action speed in healthy individuals.

Phase 3 functional MRI (fMRI)

Other

Phase 3 administers iTBS to enhance action speed in stroke patients within the first six months post-stroke, leveraging individualized action speed models to tailor interventions.

Primary outcomes

  1. variations in action speed is the reaction time

    Time frame: day 0

    variations in action speed is the reaction time measured during a simple reaction time task, in which participants respond as quickly as possible to a visual stimulus using the index finger of their preferred hand.

Secondary outcomes

  1. variation between both groups of brain connectivity values

    Time frame: day 0

    changes in brain connectivity values induced by rTMS in healthy controls and post-stroke patients.

Study contacts

Contact information is provided by the study sponsor or research team.

GODEFROY Olivier, Pr

CONTACT

[email protected]

33+322668240

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Collaborators

  • CHRU LILLE

Registry information

Acronym: NAS

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Mar 12, 2026
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.